Table 1.
Baseline characteristics
| Baseline characteristics | ||||||
|---|---|---|---|---|---|---|
| Open | MI | p value | ||||
| Total | 49 | 47 | ||||
| Gender (male, %) | 32 | 65.3% | 28 | 59.6% | 0.674 | |
| Age (years, mean ± SD) | 61.8 | 10 | 59.4 | 12.5 | 0.298 | |
| Length (cm, mean ± SD) | 169.7 | 11.1 | 166.7 | 8.3 | 0.141 | |
| Weight (kg, mean ± SD) | 72.7 | 14.6 | 73.6 | 13.6 | 0.765 | |
| BMI (kg/m3, mean ± SD) | 25.2 | 4 | 26.5 | 4.8 | 0.139 | |
| Weight loss (Yes, %) | 23 | 50.0% | 18 | 40.0% | 0.402 | |
| ASA classification | ||||||
| ASA I | 6 | 12.2% | 4 | 8.5% | 0.813* | |
| ASA II | 31 | 63.3% | 30 | 63.8% | ||
| ASA III | 12 | 24.5% | 13 | 27.7% | ||
| WHO-performance status | ||||||
| WHO 0 | 32 | 65.3% | 29 | 61.7% | 0.582* | |
| WHO 1 | 13 | 26.5% | 16 | 34.0% | ||
| WHO 2 | 4 | 8.2% | 2 | 4.3% | ||
| Smoking | 15 | 30.6% | 14 | 29.8% | 0.999 | |
| Pack years (median, IQR) | 37 | (20–60) | 20 | (10–33) | 0.115 | |
| Alcohol (Y/N) | 14 | 28.6% | 14 | 29.8% | 0.999 | |
| Units/week (median, IQR) | 7 | (3–14) | 5 | (2–12) | 0.300 | |
| Medical history | ||||||
| Cardiovascular | 24 | 49.0% | 17 | 36.5% | 0.223 | |
| Gastro-intestinal | 14 | 28.6% | 15 | 31.9% | 0.825 | |
| Endocrine | 10 | 20.4% | 13 | 27.7% | 0.477 | |
| Previous abdominal surgery | 15 | 31.3% | 12 | 25.5% | 0.650 | |
| Medication | 35 | 71.4% | 34 | 72.3% | 0.999 | |
| PPI | 23 | 52.3% | 20 | 2.0% | 0.670 | |
| OAC | 2 | 4.5% | 1 | 2.3% | 0.999 | |
| IDDM | 3 | 6.8% | 2 | 4.5% | 0.999 | |
| Preoperative workup | ||||||
| Gastroscopy location | ||||||
| Proximal | 14 | 28.6% | 13 | 27.7% | 0.979* | |
| Middle | 25 | 51.0% | 25 | 53.2% | ||
| Distal | 10 | 20.4% | 9 | 19.1% | ||
| Clinical TNM | ||||||
| T1 | 1 | 2.0% | 2 | 4.3% | 0.730* | |
| T2 | 8 | 16.3% | 9 | 19.1% | ||
| T3 | 36 | 73.5% | 30 | 63.8% | ||
| T4 | 4 | 8.2% | 6 | 12.8% | ||
| N0 | 17 | 34.7% | 17 | 36.2% | 0.711* | |
| N1 | 25 | 51.0% | 26 | 55.3% | ||
| N2 | 7 | 14.2% | 4 | 8.5% | ||
| Neoadjuvant therapy | ||||||
| ECC | 12 | 24.5% | 9 | 19.1% | 0.690* | |
| ECF | 10 | 20.4% | 9 | 19.1% | ||
| EOX | 13 | 26.5% | 13 | 27.7% | ||
| FOLFOX | 0 | 2 | 4.3%% | |||
| FLOT | 10 | 20.4% | 8 | 17.0% | ||
| Other | 4 | 8.2% | 6 | 12.8% | ||
* Additional testing within groups with Bonferroni correction showed no differences between groups